DCGI approves AstraZeneca’s Lynparza for adjuvant treatment of patients with high-risk early breast cancer Read more
AstraZeneca’s Savannah phase-II trial shows 49 per cent objective response in lung cancer patients Read more
EU approves AstraZeneca’s Lynparza for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer Read more